NASDAQ:XBIO

Xenetic Biosciences (XBIO) Stock Price, News & Analysis

Xenetic Biosciences logo
$1.40 -0.14 (-9.09%)
Closing price 11/20/2026 03:47 PM Eastern
Extended Trading
$1.46 +0.06 (+3.93%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Xenetic Biosciences Stock (NASDAQ:XBIO)

Advanced

Key Stats

Today's Range
$1.25
▼
$1.58
50-Day Range
$1.40
▼
$4.33
52-Week Range
$1.25
▼
$4.94
Volume
21,760 shs
Average Volume
23,559 shs
Market Capitalization
$3.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Xenetic Biosciences, Inc. is a biotechnology company focused on developing immuno-oncology treatments. Its XCART platform is designed to create personalized CAR T-cell therapies that recognize tumor-specific antigens on B-cell lymphomas, with the goal of targeting cancer cells while limiting effects on healthy cells.

The company’s earlier work included PolyXen, a drug-delivery platform based on polysialic acid that was designed to extend the time biologic medicines remain in the body. Xenetic’s current stated focus is advancing its XCART technology and related product candidates.

AI Generated. May Contain Errors.

Xenetic Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
6th Percentile Overall Score

XBIO MarketRank™: 
0.2918888577 of 5 stars

Xenetic Biosciences scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Xenetic Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Xenetic Biosciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Xenetic Biosciences' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Xenetic Biosciences is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Xenetic Biosciences is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Xenetic Biosciences has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.75% of the float of Xenetic Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Xenetic Biosciences has a short interest ratio ("days to cover") of 1.18, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Xenetic Biosciences has recently increased by 237.72%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Xenetic Biosciences does not currently pay a dividend.

  • Dividend Growth

    Xenetic Biosciences does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 1 news article for Xenetic Biosciences this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added Xenetic Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Xenetic Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    7.60% of the stock of Xenetic Biosciences is held by insiders.

  • Percentage Held by Institutions

    15.12% of the stock of Xenetic Biosciences is held by institutions.

  • Read more about Xenetic Biosciences' insider trading history.
Receive XBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

XBIO Stock News Headlines

Contrasting Xenetic Biosciences (XBIO) and Its Peers
Unbelievable…Congress is About to Do What?
Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washington is set to take place by November 30th. He believes it could create one of the most chaotic environments in America's history. He predicts those who understand what's happening could do very well over the next 12-18 months, while others may face steep losses. Rickards outlines the five steps he recommends.tc pixel
See More Headlines

XBIO Stock Analysis - Frequently Asked Questions

Xenetic Biosciences' stock was trading at $2.17 at the start of the year. Since then, XBIO shares have decreased by 35.5% and is now trading at $1.40.

Xenetic Biosciences, Inc. (NASDAQ:XBIO) posted its earnings results on Thursday, November, 12th. The company reported ($0.72) earnings per share for the quarter. The company earned $725.26 thousand during the quarter. Xenetic Biosciences had a negative net margin of 123.72% and a negative trailing twelve-month return on equity of 58.97%.

Xenetic Biosciences shares reverse split on Monday, May 15th 2023.The 1-10 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Xenetic Biosciences investors own include NIO (NIO), FuelCell Energy (FCEL), Plug Power (PLUG), SNDL (SNDL), AMC Entertainment (AMC), Ideanomics (IDEX) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/12/2026
Today
11/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:XBIO
CIK
1534525
Fax
N/A
Employees
2
Year Founded
2011

Profitability

EPS (Trailing Twelve Months)
($1.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$2.68 million
Net Margins
-123.72%
Pretax Margin
-123.69%
Return on Equity
-58.97%
Return on Assets
-49.54%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.15
Quick Ratio
3.15

Sales & Book Value

Annual Sales
$2.98 million
Price / Sales
1.10
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.88 per share
Price / Book
0.74

Miscellaneous

Outstanding Shares
2,340,000
Free Float
2,165,000
Market Cap
$3.28 million
Optionable
Not Optionable
Beta
2.36

Social Links

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (NASDAQ:XBIO) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners